CAR T-Cell Therapy-Associated Toxicities Could Be Mitigated With Anakinra Prophylaxis in Multiple Myeloma

The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.